Rare MYH9-ROS1 Fusion Gene-Positive Lung Adenocarcinoma Showing Response to Entrectinib Treatment: A Case Study
The c-ros oncogene 1 (ROS1) fusion gene is a rare genomic alteration detected in nearly 1–2% of lung adenocarcinomas. The major partner genes of ROS1 include CD74, SDC4, and EZR. Here, we report a case of MYH9-ROS1 fusion gene-positive lung adenocarcinoma, a rare ROS1 fusion gene. The patient was a...
Saved in:
| Published in: | Case reports in oncology Vol. 15; no. 1; pp. 376 - 381 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Basel, Switzerland
S. Karger AG
31-03-2022
Karger Publishers |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The c-ros oncogene 1 (ROS1) fusion gene is a rare genomic alteration detected in nearly 1–2% of lung adenocarcinomas. The major partner genes of ROS1 include CD74, SDC4, and EZR. Here, we report a case of MYH9-ROS1 fusion gene-positive lung adenocarcinoma, a rare ROS1 fusion gene. The patient was a woman in her 40s who was diagnosed with advanced primary lung adenocarcinoma after a thorough examination. Initial genetic testing conducted using mediastinal lymph node biopsy specimens collected by endobronchial ultrasound-guided transbronchial needle aspiration revealed no driver gene mutations, including the ROS1 fusion gene. The patient was treated with four courses of immunochemotherapy. As the disease worsened, another genetic test was conducted using FoundationOne ® CDx, and the MYH9-ROS1 fusion gene was detected. Multiple lung metastases disappeared after the administration of entrectinib; the response persisted up to a year. Adverse events of rash, dysgeusia, and peripheral edema were observed, and the patient required temporary drug interruption; however, we were able to continue entrectinib following a short-term drug interruption. This is the first report on the effectiveness of entrectinib against lung adenocarcinoma with the rare MYH9-ROS1 fusion gene. |
|---|---|
| AbstractList | The c-ros oncogene 1 (ROS1) fusion gene is a rare genomic alteration detected in nearly 1–2% of lung adenocarcinomas. The major partner genes of ROS1 include CD74, SDC4, and EZR. Here, we report a case of MYH9-ROS1 fusion gene-positive lung adenocarcinoma, a rare ROS1 fusion gene. The patient was a woman in her 40s who was diagnosed with advanced primary lung adenocarcinoma after a thorough examination. Initial genetic testing conducted using mediastinal lymph node biopsy specimens collected by endobronchial ultrasound-guided transbronchial needle aspiration revealed no driver gene mutations, including the ROS1 fusion gene. The patient was treated with four courses of immunochemotherapy. As the disease worsened, another genetic test was conducted using FoundationOne® CDx, and the MYH9-ROS1 fusion gene was detected. Multiple lung metastases disappeared after the administration of entrectinib; the response persisted up to a year. Adverse events of rash, dysgeusia, and peripheral edema were observed, and the patient required temporary drug interruption; however, we were able to continue entrectinib following a short-term drug interruption. This is the first report on the effectiveness of entrectinib against lung adenocarcinoma with the rare MYH9-ROS1 fusion gene. The fusion gene is a rare genomic alteration detected in nearly 1-2% of lung adenocarcinomas. The major partner genes of include , , and . Here, we report a case of fusion gene-positive lung adenocarcinoma, a rare fusion gene. The patient was a woman in her 40s who was diagnosed with advanced primary lung adenocarcinoma after a thorough examination. Initial genetic testing conducted using mediastinal lymph node biopsy specimens collected by endobronchial ultrasound-guided transbronchial needle aspiration revealed no driver gene mutations, including the fusion gene. The patient was treated with four courses of immunochemotherapy. As the disease worsened, another genetic test was conducted using FoundationOne CDx, and the fusion gene was detected. Multiple lung metastases disappeared after the administration of entrectinib; the response persisted up to a year. Adverse events of rash, dysgeusia, and peripheral edema were observed, and the patient required temporary drug interruption; however, we were able to continue entrectinib following a short-term drug interruption. This is the first report on the effectiveness of entrectinib against lung adenocarcinoma with the rare fusion gene. The c-ros oncogene 1 (ROS1) fusion gene is a rare genomic alteration detected in nearly 1–2% of lung adenocarcinomas. The major partner genes of ROS1 include CD74 , SDC4 , and EZR . Here, we report a case of MYH9-ROS1 fusion gene-positive lung adenocarcinoma, a rare ROS1 fusion gene. The patient was a woman in her 40s who was diagnosed with advanced primary lung adenocarcinoma after a thorough examination. Initial genetic testing conducted using mediastinal lymph node biopsy specimens collected by endobronchial ultrasound-guided transbronchial needle aspiration revealed no driver gene mutations, including the ROS1 fusion gene. The patient was treated with four courses of immunochemotherapy. As the disease worsened, another genetic test was conducted using FoundationOne® CDx, and the MYH9-ROS1 fusion gene was detected. Multiple lung metastases disappeared after the administration of entrectinib; the response persisted up to a year. Adverse events of rash, dysgeusia, and peripheral edema were observed, and the patient required temporary drug interruption; however, we were able to continue entrectinib following a short-term drug interruption. This is the first report on the effectiveness of entrectinib against lung adenocarcinoma with the rare MYH9-ROS1 fusion gene. The c-ros oncogene 1 (ROS1) fusion gene is a rare genomic alteration detected in nearly 1–2% of lung adenocarcinomas. The major partner genes of ROS1 include CD74, SDC4, and EZR. Here, we report a case of MYH9-ROS1 fusion gene-positive lung adenocarcinoma, a rare ROS1 fusion gene. The patient was a woman in her 40s who was diagnosed with advanced primary lung adenocarcinoma after a thorough examination. Initial genetic testing conducted using mediastinal lymph node biopsy specimens collected by endobronchial ultrasound-guided transbronchial needle aspiration revealed no driver gene mutations, including the ROS1 fusion gene. The patient was treated with four courses of immunochemotherapy. As the disease worsened, another genetic test was conducted using FoundationOne ® CDx, and the MYH9-ROS1 fusion gene was detected. Multiple lung metastases disappeared after the administration of entrectinib; the response persisted up to a year. Adverse events of rash, dysgeusia, and peripheral edema were observed, and the patient required temporary drug interruption; however, we were able to continue entrectinib following a short-term drug interruption. This is the first report on the effectiveness of entrectinib against lung adenocarcinoma with the rare MYH9-ROS1 fusion gene. |
| Author | Hirai, Takahiro Taniguchi, Hirokazu Ishizawa, Shin Takata, Naoki Tsuda, Takeshi Masaki, Yasuaki |
| AuthorAffiliation | a Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan b Department of Pathology, Toyama Prefectural Central Hospital, Toyama, Japan |
| AuthorAffiliation_xml | – name: b Department of Pathology, Toyama Prefectural Central Hospital, Toyama, Japan – name: a Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan |
| Author_xml | – sequence: 1 givenname: Takeshi surname: Tsuda fullname: Tsuda, Takeshi email: *Takeshi Tsuda, ttsuda-tym@umin.ac.jp – sequence: 2 givenname: Naoki surname: Takata fullname: Takata, Naoki – sequence: 3 givenname: Takahiro surname: Hirai fullname: Hirai, Takahiro – sequence: 4 givenname: Yasuaki surname: Masaki fullname: Masaki, Yasuaki – sequence: 5 givenname: Shin surname: Ishizawa fullname: Ishizawa, Shin – sequence: 6 givenname: Hirokazu orcidid: 0000-0002-1571-9558 surname: Taniguchi fullname: Taniguchi, Hirokazu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35529286$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkUtvEzEQgC1URB9w4I6QpZ44LNi7a--aQ6Uo6ksKCkrKgZNle8epQ2IHe7eo_x63W6JW4uTRzOdvZjTH6MAHDwi9p-QzpUx8IYSwsiYNfYWOKOdlwVnDDp7Fh-g4pTUhXDDO3qDDirFSlC0_QmGhIuBvP69EsZgvKb4YkgseX4KH4ntIrnd3gGeDX-FJBz4YFY3zYavw8jb8cTm9gLQLPgHuAz73fQTTO-80vomg-i34_iue4KnKwLIfuvu36LVVmwTvnt4T9OPi_GZ6Vczml9fTyawwNW9ooXRprWi1MdTWlnLaVcqarmoY45qByoElpWbCGGCi5lYLxihTtYEaaMOrE3Q9erug1nIX3VbFexmUk4-JEFdSxd6ZDUgCQpMGqCC6rm1DW6hZ1ZmSa2tyJ51dZ6NrN-gtdCYvFdXmhfRlxbtbuQp3UpCKCSKy4PRJEMPvAVIv12GIPu8vS84Eb1tKykx9GikTQ0oR7L4DJfLhznJ_58x-fD7Snvx32Ax8GIFfKq4g7oH9_9P_lqeL-UjIXWerv8OfucQ |
| CitedBy_id | crossref_primary_10_1016_j_rmcr_2023_101893 crossref_primary_10_1038_s41598_024_52006_6 crossref_primary_10_1007_s40278_022_18220_9 crossref_primary_10_1016_j_cllc_2023_03_015 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s). Published by S. Karger AG, Basel Copyright © 2022 by S. Karger AG, Basel. 2022 The Author(s). Published by S. Karger AG, Basel . This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2022 by S. Karger AG, Basel 2022 |
| Copyright_xml | – notice: 2022 The Author(s). Published by S. Karger AG, Basel – notice: Copyright © 2022 by S. Karger AG, Basel. – notice: 2022 The Author(s). Published by S. Karger AG, Basel . This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2022 by S. Karger AG, Basel 2022 |
| DBID | M-- NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI PRINS 5PM DOA |
| DOI | 10.1159/000524071 |
| DatabaseName | Karger Open Access PubMed CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Central (Alumni) |
| DatabaseTitleList | ProQuest One Academic Eastern Edition CrossRef PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1662-6575 |
| EndPage | 381 |
| ExternalDocumentID | oai_doaj_org_article_0e9b07e190b44f718e453dc26bfcea3b 10_1159_000524071 35529286 524071 |
| Genre | Case Reports |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | --- 0~B 29B 3O. 3V. 53G 5GY 5VS 6J9 7X7 8FI 8FJ ABDBF ABPAZ ABUWG ACGFS ADBBV AEGXH AEYAO AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZPMC BAWUL BCNDV BENPR BPHCQ BVXVI CAG CCPQU CYUIP DIK E0A E3Z EBS F5P FB. FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR KQ8 M-- M48 M~E O1H O5R O5S OK1 PQQKQ PROAC RKO RNS RPM TR2 UKHRP 4.4 ADRAZ C1A COF EJD IPNFZ ITC NPM RIG AAYXX CITATION 7XB 8FK K9. PQEST PQUKI PRINS 5PM |
| ID | FETCH-LOGICAL-c4671-ab2ff98bcc1f4f161d3afcd37556b5ea375f02b59cce5946fb95515a4ce4e1763 |
| IEDL.DBID | RPM |
| ISSN | 1662-6575 |
| IngestDate | Tue Oct 22 15:11:00 EDT 2024 Tue Sep 17 21:21:28 EDT 2024 Thu Oct 10 19:28:37 EDT 2024 Thu Nov 21 23:44:50 EST 2024 Sat Sep 28 08:41:02 EDT 2024 Thu Sep 05 17:58:16 EDT 2024 Thu Aug 29 12:04:33 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | MYH9-ROS1 fusion gene Entrectinib Lung adenocarcinoma Erythema |
| Language | English |
| License | This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Copyright © 2022 by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4671-ab2ff98bcc1f4f161d3afcd37556b5ea375f02b59cce5946fb95515a4ce4e1763 |
| ORCID | 0000-0002-1571-9558 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035909/ |
| PMID | 35529286 |
| PQID | 2659688102 |
| PQPubID | 2047992 |
| PageCount | 6 |
| ParticipantIDs | pubmed_primary_35529286 crossref_primary_10_1159_000524071 proquest_journals_2659688102 doaj_primary_oai_doaj_org_article_0e9b07e190b44f718e453dc26bfcea3b karger_primary_524071 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9035909 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-31 |
| PublicationDateYYYYMMDD | 2022-03-31 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Basel – name: Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com |
| PublicationTitle | Case reports in oncology |
| PublicationTitleAlternate | Case Rep Oncol |
| PublicationYear | 2022 |
| Publisher | S. Karger AG Karger Publishers |
| Publisher_xml | – name: S. Karger AG – name: Karger Publishers |
| References | Xu H, Zhang Q, Liang L, Li J, Liu Z, Li W, . Crizotinib versus platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. Cancer Med. 2020;9(10):3328–36. Jain A, Fujioka N, Patel M. Immune checkpoint inhibitors in ROS1-rearranged non-small cell lung cancer: a report of two cases. J Thorac Oncol. 2019;14(8):e165–7. Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, . NTRK3 kinase fusions in Spitz tumours. J Pathol. 2016;240(3):282–90. Nishiyama A, Hattori Y, Takeuchi S, Tanimoto A, Satouchi M, Murayama T, . Severe skin toxicity caused by sequential anti-PD-1 antibody and Alectinib in non-small-cell lung cancer: a report of two cases and a literature review. Intern Med. 2022:7472–21. Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, . Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):261–70. Lamant L, Gascoyne RD, Duplantier MM, Armstrong F, Raghab A, Chhanabhai M, . Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer. 2003;37(4):427–32. AmoyDx OG. ROS1 attached document. Available from: https://www.info.pmda.go.jp/downfiles/ivd/PDF/850278_22900EZX00002000_A_01_02.ppd. Sun Y, Pei L, Luo N, Chen D, Meng L. A novel MYH9-RET fusion occurrence and EGFR T790M loss as an acquired resistance mechanism to Osimertinib in a patient with lung adenocarcinoma: a case report. Onco Targets Ther. 2020;13:11177–81. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71. Oncomine Dx target test part I: test description and performance characteristics USER GUIDE. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160045S019C.pdf. Uhara H, Kiyohara Y, Tsuda A, Takata M, Yamazaki N. Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan. Clin Transl Oncol. 2018;20(2):169–75. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, . ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–70. Pecci A, Ma X, Savoia A, Adelstein RS. MYH9: structure, functions and role of non-muscle myosin IIA in human disease. Gene. 2018;664:152–67. Cui M, Han Y, Li P, Zhang J, Ou Q, Tong X, . Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. Mol Oncol. 2020;14(11):2787–95. Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, . Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. J Thorac Oncol. 2017;12(2):258–68. |
| References_xml | |
| SSID | ssj0069565 |
| Score | 2.287097 |
| Snippet | The c-ros oncogene 1 (ROS1) fusion gene is a rare genomic alteration detected in nearly 1–2% of lung adenocarcinomas. The major partner genes of ROS1 include... The fusion gene is a rare genomic alteration detected in nearly 1-2% of lung adenocarcinomas. The major partner genes of include , , and . Here, we report a... The c-ros oncogene 1 (ROS1) fusion gene is a rare genomic alteration detected in nearly 1–2% of lung adenocarcinomas. The major partner genes of ROS1 include... |
| SourceID | doaj pubmedcentral proquest crossref pubmed karger |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 376 |
| SubjectTerms | Biopsy Bladder Cancer therapies Case Report Case reports entrectinib Erythema Genes Kinases lung adenocarcinoma Lung cancer Lymphatic system Metastasis Mutation myh9-ros1 fusion gene Pharmaceuticals Pleural effusion Taste disorders Tomography |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB7BHlAviFfb0KWyENeoiWMncW_Lsqs98NIuSO0pih1boKoJWlhQ_33HdhJ1USUuXO3Ycmbs-WaSmc8AJ3GsdaQ4bl6qacjyqApLEYtQVizBeEJmwlW9zxbZ5Y_8bGJpcvqrvmxOmKcH9oL7Fmkho0wjbknGDFpSzXhSKZpKo3SZSGd9o7QLprwNTtHr5y2PEOK1u7nOhS5r6ONI-hF5ftmc6-X_XMzXmZL_QM90B7Zbn5GM_Fp3YUPXe7B10f4V34dmXi41ufg5E-H8ahGT6cp-AiOWUTq8dklZz5qc46kmI7QyCF5LHNf8LsnirnlB6CJznyiryVNDJpboEo1gfS_JTZeF_p2MyBjxjti0wz8HcDud3IxnYXuRQqjQDsZhKakxIpdKxYYZ9PGqpDSqSjLOU8lRihk3EZVcKFuUxVIjBTpSvGRKMx2jBfoIg7qp9WcgVrIJF6XBuI0pKQVDkKWVkjQxuaEigONOwMWD58soXJzBRdFrIYBTK_r-AUtx7RpQ8UWr-OItxQdw4BXXT9NNPnzVPp5f-a7ioTLY3am5aI_rY0FTLtI8R2crgE9e4_1odMiooHkaQLa2F9ZWv95T3985om5h-REjcfger_sFPlBbeeHKIYcweFqu9BFsPlarr27r_wXvqQjq priority: 102 providerName: Directory of Open Access Journals |
| Title | Rare MYH9-ROS1 Fusion Gene-Positive Lung Adenocarcinoma Showing Response to Entrectinib Treatment: A Case Study |
| URI | https://karger.com/doi/10.1159/000524071 https://www.ncbi.nlm.nih.gov/pubmed/35529286 https://www.proquest.com/docview/2659688102 https://pubmed.ncbi.nlm.nih.gov/PMC9035909 https://doaj.org/article/0e9b07e190b44f718e453dc26bfcea3b |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb5swFH5qeqh6mbqt2-gvWdOuNGBswL1laaIclrZKOmk7IWzsNtoCEW1a7b_fs4GoqXbaLcIxsvye3_cefO8D4EsYah0ojs5LNfVZGhR-LkLhy4JFWE_IRLiu98k8ufqRXo6sTA7vemEcaV_JxXn5e3leLu4dt3K1VP2OJ9a_mQ6F1Z0LRL8HPcwNuxK9Cb8xJvy8lRBCqHYfrXNVyz7sIbZS4dqmX2CQk-pH_Pllmdf1vxLN13zJFwA0PoA3beZIBs0K38KOLt_B3rR9N_4eqlleazL9ORH-7HoekvHaPggjVlfav3HUrCdNvuHZJgOMNQhhNc6rljmZ31fPCGBk1tBlNXmsyMjKXWIoLBeS3HZc9AsyIENEPWLJh38O4ft4dDuc-O3nFHyF0TD0c0mNEalUKjTMYKZXRLlRRZRwHkuuc_xhAiq5ULY1i8VGCkyneM6UZjrEOPQBdsuq1J-A2E1GE-QGqzempBQMoZYWStLIpIYKDz53G5ytGtWMzFUbXGQbg3jw1W795g9W6NpdqOq7rDV3Fmghg0Rj2iIZMwikmvGoUDSWRuGSpQeHjeE2t-lufvLq-nB23Qxlq8LgcGfmrD20DxmNuYjTFFMuDz42Ft_M7lzHg2TLF7ZWvz2C3uvkultvPfrvmcewT23TheuEPIHdx3qtT6H3UKzP3COEM3cA_gId3Qmd |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED6xIY298HODwAAL8Zo1cewk5q2UVkW029QWCZ6i2LFZBU2qbAXx33N2kmqdeNpbZdeR0zvfd5d-9wXgfRhqHSiOzks19VkaFH4uQuHLgkVYT8hEuK738Tw5-5Z-GlqZHN71wjjSvpLL0_LX6rRcXjpu5Xqleh1PrHcxHQirOxeI3h7cx_MaBF2R3gTgGFN-3ooIIVi719a5uuUQDhBdqXCN0zdQyIn1IwL9tNzr-n-p5m3G5A0IGj264-Yfw8M25yT9ZvoJ3NPlUziYtv-qP4NqlteaTL-PhT87n4dktLGP0IhVpPYvHKnrtyYTjAqkj1EKwa_GddUqJ_PL6g9CH5k1RFtNrisytEKZGETLpSSLjsX-gfTJAPGSWNri3yP4OhouBmO_fRGDrzCOhn4uqTEilUqFhhnMEYsoN6qIEs5jyXWOH0xAJRfKNnWx2EiBiRjPmdJMhxjBjmG_rEr9Aog1Dt5_brDuY0pKwRCkaaEkjUxqqPDgXWeYbN3obWSuTuEi2xrSg4_WZNsvWIlsN1DVP7L2t84CLWSQaEx4JGMGIVgzHhWKxtIo3LL04Kgx-PYy3cVPbo0PZufNVLYuDE537pG1x_0qozEXcZpisubB88ZTtqs7l_Mg2fGhnd3vzqDrOKHv1lVe3nnlW3gwXkwn2eTz2ZdXcEht64brpzyB_et6o1_D3lWxeeOOzz_Xbh4z |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwED6xIVV74ecYgQEW4jVr4thJzFvpWhWxblU7JHiKYsdmFTSpshXEf8_ZSap14gneojiO0tz5vrvmu88A78JQ60BxdF6qqc_SoPBzEQpfFizCekImwnW9TxbJ-Zf0dGRlcrZbfTnSvpLLk_LH6qRcXjlu5Xql-h1PrD-bDoXVnQtEf12Y_h7cxzUb0K5Qb4JwjGk_b4WEELDd1nWudjmAHiIsFa55-hYSOcF-RKHvln9d_y3dvMuavAVD44f_8QMewYM29ySD5pLHcE-XT6A3bb-uP4VqnteaTL9OhD-_WIRkvLF_pRGrTO3PHLnrpyZnGB3IAKMVgmCN86pVThZX1S-EQDJvCLea3FRkZAUzMZiWS0kuOzb7ezIgQ8RNYumLvw_h83h0OZz47YYMvsJ4Gvq5pMaIVCoVGmYwVyyi3KgiSjiPJdc5HpiASi6Ube5isZECEzKeM6WZDjGSPYP9sir1cyDWQPgOcoP1H1NSCoZgTQslaWRSQ4UHbzvjZOtGdyNz9QoX2daYHnywZtteYKWy3Ymq_pa17zsLtJBBojHxkYwZhGLNeFQoGkuj8JGlB4eN0be36W5-fOf8cH7RDGVoNxzuXCRrl_11RmMu4jTFpM2Do8ZbtrM7t_Mg2fGjnaffHUH3cYLfrbu8-OeZb6A3Ox1nZx_PP72EA2o7OFxb5THs39Qb_Qr2rovNa7eC_gDUyiCz |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rare+MYH9-ROS1+Fusion+Gene-Positive+Lung+Adenocarcinoma+Showing+Response+to+Entrectinib+Treatment%3A+A+Case+Study&rft.jtitle=Case+reports+in+oncology&rft.au=Tsuda%2C+Takeshi&rft.au=Takata%2C+Naoki&rft.au=Hirai%2C+Takahiro&rft.au=Masaki%2C+Yasuaki&rft.date=2022-03-31&rft.pub=S.+Karger+AG&rft.eissn=1662-6575&rft.volume=15&rft.issue=1&rft.spage=376&rft.epage=381&rft_id=info:doi/10.1159%2F000524071&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1662-6575&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1662-6575&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1662-6575&client=summon |